Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Marques, Catarina ^a   Mega, Cristina ^a,b   Gonçalves, Andreia ^a   Rodrigues Santos, Paulo ^a,c   Teixeira Lemos, Edite ^a,b   Teixeira, Frederico ^a   Fontes Ribeiro, Carlos ^a   Reis, Flávio ^a   Fernandes, Rosa ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b POLYTECHNIC INSTITUTE OF VISEU   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; INTERLEUKIN 1BETA; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; SITAGLIPTIN; TUMOR NECROSIS FACTOR ALPHA; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFICACY; EXPERIMENTAL DIABETIC NEUROPATHY; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; INSULIN RELEASE; KIDNEY CELL; KIDNEY FUNCTION; KIDNEY INJURY; NICK END LABELING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN CONTENT; PROTEIN LOCALIZATION; RAT; RENAL PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WEIGHT REDUCTION; WESTERN BLOTTING; ZUCKER DIABETIC FATTY RAT; ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; INFLAMMATION; KIDNEY; METABOLISM; ZUCKER RAT;

ANIMALS; APOPTOSIS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; INFLAMMATION; KIDNEY; PYRAZINES; RATS; RATS, ZUCKER; TRIAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899895454     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/538737     Document Type: Article

References (79)

1. Dronavalli S., Duka I., Bakris G. L., The pathogenesis of diabetic nephropathy. Nature Clinical Practice Endocrinology and Metabolism 2008 4 8 444 452 2-s2.0-47949127622 10.1038/ncpendmet0894
2. Kanwar Y. S., Wada J., Sun L., Diabetic nephropathy: mechanisms of renal disease progression. Experimental Biology and Medicine (Maywood) 2008 233 1 4 11 10.3181/0705-MR-134
3. Jefferson J. A., Shankland S. J., Pichler R. H., Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney International 2008 74 1 22 36 2-s2.0-45249108429 10.1038/ki.2008.128 (Pubitemid 351841893)
4. Magee G. M., Bilous R. W., Cardwell C. R., Hunter S. J., Kee F., Fogarty D. G., Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 2009 52 4 691 697 2-s2.0-61449183458 10.1007/s00125-009-1268-0
5. Noh H., King G. L., The role of protein kinase C activation in diabetic nephropathy. Kidney International 2007 106 S49 S53 2-s2.0-35348816905 (Pubitemid 47172561)
6. Tanji N., Markowitz G. S., Fu C., Kislinger T., Taguchi A., Pischetsrieder M., Stern D., Schmidt A. M., D'Agati V. D., Expression of advanced glycation end products and their cellular receptor RAGE diabetic nephropathy and nondiabetic renal disease. Journal of the American Society of Nephrology 2000 11 9 1656 1666 2-s2.0-0033848466
7. Dunlop M., Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney International 2000 58 77 S3 S12 2-s2.0-0033857113
8. Kolm-Litty V., Sauer U., Nerlich A., Lehmann R., Schleicher E. D., High glucose-induced transforming growth factor β 1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. Journal of Clinical Investigation 1998 101 1 160 169 2-s2.0-0031975643 (Pubitemid 28058915)
9. Forbes J. M., Coughlan M. T., Cooper M. E., Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008 57 6 1446 1454 2-s2.0-48249085391 10.2337/db08-0057
10. Saraheimo M., Teppo A.-M., Forsblom C., Fagerudd J., Groop P.-H., Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients. Diabetologia 2003 46 10 1402 1407 2-s2.0-0142061945 10.1007/s00125-003-1194-5 (Pubitemid 37297211)
11. Dalla Vestra M., Mussap M., Gallina P., Bruseghin M., Cernigoi A. M., Saller A., Plebani M., Fioretto P., Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. Journal of the American Society of Nephrology 2005 16 3, supplement 1 S78 S82 2-s2.0-20844458389 10.1681/ASN.2004110961 (Pubitemid 41725090)
12. Nelson C. L., Karschimkus C. S., Dragicevic G., Packham D. K., Wilson A. M., O'Neal D., Becker G. J., Best J. D., Jenkins A. J., Systemic and vascular inflammation is elevated in early IgA and type 1 diabetic nephropathies and relates to vascular disease risk factors and renal function. Nephrology Dialysis Transplantation 2005 20 11 2420 2426 2-s2.0-27644450540 10.1093/ndt/gfi067 (Pubitemid 41548866)
13. Lim A. K., Tesch G. H., Inflammation in diabetic nephropathy. Mediators of Inflammation 2012 2012 12 146154 10.1155/2012/146154
14. Rivero A., Mora C., Muros M., García J., Herrera H., Navarro-González J. F., Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clinical Science 2009 116 6 479 492 2-s2.0-65249102179 10.1042/CS20080394
15. Sanchez-Niño M.-D., Benito-Martin A., Ortiz A., New paradigms in cell death in human diabetic nephropathy. Kidney International 2010 78 8 737 744 2-s2.0-77957595369 10.1038/ki.2010.270
16. Wagener F. A. D. T. G., Dekker D., Berden J. H., Scharstuhl A., van der Vlag J., The role of reactive oxygen species in apoptosis of the diabetic kidney. Apoptosis 2009 14 12 1451 1458 2-s2.0-70449122033 10.1007/s10495-009- 0359-1
17. Susztak K., Raff A. C., Schiffer M., Böttinger E. P., Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006 55 1 225 233 2-s2.0-33644783770 10.2337/diabetes.55.1.225 (Pubitemid 43343319)
18. Kang B. P. S., Frencher S., Reddy V., Kessler A., Malhorta A., Meggs L. G., High glucose promotes mesangial cell apoptosis by oxidant-dependent mechanism. American Journal of Physiology: Renal Physiology 2003 284 3 F455 F466 2-s2.0-0037369416 (Pubitemid 36227906)
19. Verzola D., Bertolotto M. B., Villaggio B., Ottonello L., Dallegri F., Frumento G., Berruti V., Gandolfo M. T., Garibotto G., Deferrari G., Taurine prevents apoptosis induced by high ambient glucose in human tubule renal cells. Journal of Investigative Medicine 2002 50 6 443 451 2-s2.0-18644385337 (Pubitemid 35278685)
20. Scheen A. J., DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes and Metabolism 2012 38 2 89 101 2-s2.0-84859721063 10.1016/j.diabet.2011.11.001
21. Grunberger G., Novel therapies for the management of type 2 diabetes mellitus: part 2-addressing the incretin defect in the clinical setting in 2013. Journal of Diabetes 2013 5 3 241 253
22. Drucker D. J., The biology of incretin hormones. Cell Metabolism 2006 3 3 153 165 2-s2.0-33644618433 10.1016/j.cmet.2006.01.004
23. Nauck M. A., Homberger E., Siegel E. G., Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. Journal of Clinical Endocrinology and Metabolism 1986 63 2 492 498 2-s2.0-0022461548 (Pubitemid 16035703)
24. Ahrén B., Simonsson E., Larsson H., Landin-Olsson M., Torgeirsson H., Jansson P.-A., Sandqvist M., Båvenholm P., Efendic S., Eriksson J. W., Dickinson S., Holmes D., Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002 25 5 869 875 2-s2.0-0036583164 10.2337/diacare.25.5.869 (Pubitemid 41094285)
25. Kim D., Wang L., Beconi M., Eiermann G. J., Fisher M. H., He H., Hickey G. J., Kowalchick J. E., Leiting B., Lyons K., Marsilio F., McCann M. E., Patel R. A., Petrov A., Scapin G., Patel S. B., Roy R. S., Wu J. K., Wyvratt M. J., Zhang B. B., Zhu L., Thornberry N. A., Weber A. E., (2R)-4-Oxo-4-[3- (trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a] pyrazin-7(8H)-yl]-1-(2,4,5- trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Journal of Medicinal Chemistry 2005 48 1 141 151 2-s2.0-19944427998 10.1021/jm0493156 (Pubitemid 40105255)
26. Aschner P., Kipnes M. S., Lunceford J. K., Sanchez M., Mickel C., Williams-Herman D. E., Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006 29 12 2632 2637 2-s2.0-33845472504 10.2337/dc06-0703 (Pubitemid 44912190)
27. Raz I., Hanefeld M., Xu L., Caria C., Williams-Herman D., Khatami H., Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006 49 11 2564 2571 2-s2.0-33845489598 10.1007/s00125-006-0416-z
28. Nonaka K., Kakikawa T., Sato A., Okuyama K., Fujimoto G., Kato N., Suzuki H., Hirayama Y., Ahmed T., Davies M. J., Stein P. P., Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Research and Clinical Practice 2008 79 2 291 298 2-s2.0-38349126264 10.1016/j.diabres.2007.08.021
29. Drucker D. J., Nauck M. A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet 2006 368 9548 1696 1705 2-s2.0-33846006173 10.1016/S0140-6736(06)69705-5 (Pubitemid 46048557)
30. Mu J., Woods J., Zhou Y.-P., Roy R. S., Li Z., Zycband E., Feng Y., Zhu L., Li C., Howard A. D., Moller D. E., Thornberry N. A., Zhang B. B., Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β -cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006 55 6 1695 1704 2-s2.0-33748331194 10.2337/db05-1602 (Pubitemid 44324122)
31. Gonçalves A., Leal E., Paiva A., Teixeira Lemos E., Teixeira F., Ribeiro C. F., Reis F., Ambrósio A. F., Fernandes R., Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model. Diabetes, Obesity and Metabolism 2012 14 5 454 463 2-s2.0-84859444000 10.1111/j.1463-1326.2011.01548.x
32. Read P. A., Khan F. Z., Heck P. M., Hoole S. P., Dutka D. P., DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circulation 2010 3 2 195 201 2-s2.0-77951934948 10.1161/CIRCIMAGING. 109.899377
33. Vaghasiya J., Sheth N., Bhalodia Y., Manek R., Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes. Regulatory Peptides 2011 166 1-3 48 54 2-s2.0-78650175802 10.1016/j.regpep.2010.08.007
34. Liu W. J., Xie S. H., Liu Y. N., Kim W., Jin H. Y., Park S. K., Shao Y. M., Park T. S., Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. Journal of Pharmacology and Experimental Therapeutics 2012 340 2 248 255 2-s2.0-84855995621 10.1124/jpet.111.186866
35. Mega C., Teixeira de Lemos E., Vala H., Fernandes R., Oliveira J., Mascarenhas-Melo F., Teixeira F., Reis F., Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Experimental Diabetes Research 2011 2011 2-s2.0-84855611505 10.1155/2011/162092 162092
36. Yozai K., Shikata K., Sasaki M., Tone A., Ohga S., Usui H., Okada S., Wada J., Nagase R., Ogawa D., Shikata Y., Makino H., Methotrexate prevents renal injury in experimental diabetic rats via anti-inflammatory actions. Journal of the American Society of Nephrology 2005 16 11 3326 3338 2-s2.0-33644876409 10.1681/ASN.2004111011 (Pubitemid 46179336)
37. Tone A., Shikata K., Sasaki M., Ohga S., Yozai K., Nishishita S., Usui H., Nagase R., Ogawa D., Okada S., Shikata Y., Wada J., Makino H., Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats. Diabetologia 2005 48 11 2402 2411 2-s2.0-27744449610 10.1007/s00125-005- 1945-6 (Pubitemid 41618933)
38. Ohga S., Shikata K., Yozai K., Okada S., Ogawa D., Usui H., Wada J., Shikata Y., Makino H., Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF- B activation. American Journal of Physiology: Renal Physiology 2007 292 4 F1141 F1150 2-s2.0-34147213227 10.1152/ajprenal.00288.2005 (Pubitemid 46578056)
39. Peterson R. G., Shaw W. N., Neel M. A., Zucker diabetic fatty rat as a model for non-insulin-dependent diabetes mellitus. ILAR Journal 1990 32 3 16 19
40. Janssen U., Phillips A. O., Floege J., Rodent models of nephropathy associated with type II diabetes. Journal of Nephrology 1999 12 3 159 172 2-s2.0-0032777587 (Pubitemid 29370823)
41. Phillips A. O., Janssen U., Floege J., Progression of diabetic nephropathy. Insights from cell culture studies and animal models. Kidney and Blood Pressure Research 1999 22 1-2 81 97 2-s2.0-0033024642 10.1159/000025912 (Pubitemid 29243450)
42. Vandesompele J., de Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman F., Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology 2002 3 7 RESEARCH0034 2-s2.0-0037129827
43. Livak K. J., Schmittgen T. D., Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001 25 4 402 408 2-s2.0-0035710746 10.1006/meth.2001.1262 (Pubitemid 34164012)
44. Reis F., Ferreira L., Teixeira-de-Lemos E., Pinto F., Parada B., Mega C., Vala H., Pinto R., Garrido P., Sereno J., Fernandes R., Santos P., Velada I., Melo A., Nunes S., Teixeira F., Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators of Inflammation 2010 2010 2-s2.0-77955406467 10.1155/2010/592760 592760
45. Xiang J., Chao D. T., Korsmeyer S. J., BAX-induced cell death may not require interleukin 1 β -converting enzyme-like proteases. Proceedings of the National Academy of Sciences of the United States of America 1996 93 25 14559 14563 2-s2.0-0029906828 10.1073/pnas.93.25.14559 (Pubitemid 26419006)
46. Kluck R. M., Degli Esposti M., Perkins G., Renken C., Kuwana T., Bossy-Wetzel E., Goldberg M., Allen T., Barber M. J., Green D. R., Newmeyer D. D., The pro-apoptotic proteins, Bid and Bax, cause a limited permeabilization of the mitochondrial outer membrane that is enhanced by cytosol. Journal of Cell Biology 1999 147 4 809 822 2-s2.0-0033571045 10.1083/jcb.147.4.809
47. Matsubara J., Sugiyama S., Akiyama E., Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circulation Journal 2013 77 5 1337 1344 10.1253/circj.CJ-12-1168
48. Apaijai N., Pintana H., Chattipakorn S. C., Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats. British Journal of Pharmacology 2013 169 5 1048 1057 10.1111/bph.12176
49. Barnett A., DPP-4 inhibitors and their potential role in the management of type 2 diabetes. International Journal of Clinical Practice 2006 60 11 1454 1470 2-s2.0-33749834648 10.1111/j.1742-1241.2006.01178.x (Pubitemid 44560347)
50. Kirino Y., Sato Y., Kamimoto T., Kawazoe K., Minakuchi K., Nakahori Y., Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: A streptozotocin-induced model using wild-type and DPP4-deficient rats. Journal of Endocrinology 2009 200 1 53 61 2-s2.0-67449155340 10.1677/JOE-08-0424
51. Pala L., Mannucci E., Pezzatini A., Ciani S., Sardi J., Raimondi L., Ognibene A., Cappadona A., Vannelli B. G., Rotella C. M., Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochemical and Biophysical Research Communications 2003 310 1 28 31 2-s2.0-0141737555 10.1016/j.bbrc.2003.08.111 (Pubitemid 37162757)
52. Augustyns K., Bal G., Thonus G., Belyaev A., Zhang X. M., Bollaert W., Lambeir A. M., Durinx C., Goossens F., Haemers A., The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors. Current Medicinal Chemistry 1999 6 4 311 327 2-s2.0-0032961099 (Pubitemid 29226115)
53. Matheeussen V., Baerts L., de Meyer G., de Keulenaer G., van der Veken P., Augustyns K., Dubois V., Scharpé S., De Meester I., Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. The Biological Chemistry 2011 392 3 189 198 2-s2.0-79953320085 10.1515/BC.2011.002
54. Fujita H., Morii T., Fujishima H., The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney International 2013 85 3 579 589
55. Picatoste B., Ramírez E., Caro-Vadillo A., Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. PLoS ONE 2013 8 10 0078330 10.1371/journal.pone.0078330
56. Kodera R., Shikata K., Kataoka H. U., Takatsuka T., Miyamoto S., Sasaki M., Kajitani N., Nishishita S., Sarai K., Hirota D., Sato C., Ogawa D., Makino H., Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011 54 4 965 978 2-s2.0-79953826349 10.1007/s00125-010-2028-x
57. Kodera R., Shikata K., Takasuta T., Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes. Biochemical and Biophysical Research Communications 2014 443 3 828 833 10.1016/j.bbrc.2013.12.049
58. Navarro J. F., Mora C., Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy. TheScientificWorldJOURNAL 2006 6 908 917 2-s2.0-33747385291 10.1100/tsw.2006.179 (Pubitemid 44252722)
59. Wang Y., Landheer S., van Gilst W. H., Attenuation of renovascular damage in Zucker diabetic fatty rat by NWT-03, an egg protein hydrolysate with ACE- and DPP4-inhibitory Activity. PLoS ONE 2012 7 10 e46781
60. Wu Y.-G., Lin H., Qi X.-M., Wu G.-Z., Qian H., Zhao M., Shen J.-J., Lin S.-T., Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes. International Immunopharmacology 2006 6 3 445 453 2-s2.0-31044451264 10.1016/j.intimp.2005.09.006 (Pubitemid 43120459)
61. Dobrian A. D., Ma Q., Lindsay J. W., Leone K. A., Ma K., Coben J., Galkina E. V., Nadler J. L., Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. American Journal of Physiology: Endocrinology and Metabolism 2011 300 2 E410 E421 2-s2.0-79251541159 10.1152/ajpendo.00463.2010
62. Mezzano S., Droguett A., Eugenia Burgos M., Ardiles L. G., Flores C. A., Aros C. A., Caorsi I., Vío C. P., Ruiz-Ortega M., Egido J., Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney International 2003 64 86 S64 S70 2-s2.0-17144469021 (Pubitemid 37159630)
63. Furuta T., Saito T., Ootaka T., Soma J., Obara K., Abe K., Yoshinaga K., The role of macrophages in diabetic glomerulosclerosis. American Journal of Kidney Diseases 1993 21 5 480 485 2-s2.0-0027231859 (Pubitemid 23160508)
64. Chow F., Ozols E., Nikolic-Paterson D. J., Atkins R. C., Tesch G. H., Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney International 2004 65 1 116 128 2-s2.0-0346101486 10.1111/j.1523-1755.2004.00367.x (Pubitemid 38037496)
65. Ninichuk V., Khandoga A. G., Segerer S., Loetscher P., Schlapbach A., Revesz L., Feifel R., Khandoga A., Krombach F., Nelson P. J., Schlöndorff D., Anders H.-J., The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice. American Journal of Pathology 2007 170 4 1267 1276 2-s2.0-34247892356 10.2353/ajpath.2007.060937 (Pubitemid 47339334)
66. Chow F. Y., Nikolic-Paterson D. J., Ozols E., Atkins R. C., Rollin B. J., Tesch G. H., Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney International 2006 69 1 73 80 2-s2.0-30944456936 10.1038/sj.ki.5000014 (Pubitemid 43117741)
67. Morcos M., Sayed A. A. R., Bierhaus A., Yard B., Waldherr R., Merz W., Kloeting I., Schleicher E., Mentz S., Abd el Baki R. F., Tritschler H., Kasper M., Schwenger V., Hamann A., Dugi K. A., Schmidt A.-M., Stern D., Ziegler R., Haering H. U., Andrassy M., Van der Woude F., Nawroth P. P., Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 2002 51 12 3532 3544 2-s2.0-0036895708 (Pubitemid 35403461)
68. Guijarro C., Egido J., Transcription factor- B (NF- B) and renal disease. Kidney International 2001 59 2 415 424 2-s2.0-0035137324 10.1046/j.1523-1755. 2001.059002415.x (Pubitemid 32157906)
69. Lee H. S., Mechanisms and consequences of hypertriglyceridemia and cellular lipid accumulation in chronic kidney disease and metabolic syndrome. Histology and Histopathology 2011 26 12 1599 1610 2-s2.0-80053981434
70. Kim S.-J., Winter K., Nian C., Tsuneoka M., Koda Y., McIntosh C. H. S., Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic β -cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the Forkhead transcription factor Foxo1, and down-regulation of bax expression. The Journal of Biological Chemistry 2005 280 23 22297 22307 2-s2.0-20444491588 10.1074/jbc.M500540200 (Pubitemid 40827886)
71. Wang Q., Brubaker P., Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 2002 45 9 1263 1273 2-s2.0-0036381989 10.1007/s00125-002-0828-3
72. Marzioni M., Alpini G., Saccomanno S., Candelaresi C., Venter J., Rychlicki C., Fava G., Francis H., Trozzi L., Benedetti A., Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. Gut 2009 58 7 990 997 2-s2.0-67649637819 10.1136/gut.2008.150870
73. Liu J.-H., Yin F., Guo L.-X., Deng X.-H., Hu Y.-H., Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway. Acta Pharmacologica Sinica 2009 30 2 159 165 2-s2.0-65349142455 10.1038/aps.2008.25
74. Qin Z., Sun Z., Huang J., Hu Y., Wu Z., Mei B., Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid- β peptide (1-42). Neuroscience Letters 2008 444 3 217 221 2-s2.0-52249112474 10.1016/j.neulet.2008.08.047
75. Zhan Y., Sun H. L., Chen H., Glucagon-like peptide-1 (GLP-1) protects vascular endothelial cells against advanced glycation end products (AGEs)-induced apoptosis. Medical Science Monitor 2012 18 7 BR286 BR291 10.12659/MSM.883207
76. Natalicchio A., de Stefano F., Orlando M. R., Melchiorre M., Leonardini A., Cignarelli A., Labarbuta R., Marchetti P., Perrini S., Laviola L., Giorgino F., Exendin-4 prevents c-Jun N-terminal protein kinase activation by Tumor Necrosis Factor- α (TNF α) and inhibits TNF α -induced apoptosis in insulin-secreting cells. Endocrinology 2010 151 5 2019 2029 2-s2.0-77953148018 10.1210/en.2009-1166
77. Quoyer J., Longuet C., Broca C., Linck N., Costes S., Varin E., Bockaert J. L., Bertrand G., Dalle S., GLP-1 mediates antiapoptotic effect by phosphorylating bad through a β -arrestin 1-mediated ERK1/2 activation in pancreatic β -cells. The Journal of Biological Chemistry 2010 285 3 1989 2002 2-s2.0-76249122645 10.1074/jbc.M109.067207
78. Tews D., Lehr S., Hartwig S., Osmers A., Paslack W., Eckel J., Anti-apoptotic action of exendin-4 in INS-1 beta cells: comparative protein pattern analysis of isolated mitochondria. Hormone and Metabolic Research 2009 41 4 294 301 2-s2.0-65649095207 10.1055/s-0028-1105911
79. Hendarto H., Inoguchi T., Maeda Y., Ikeda N., Zheng J., Takei R., Yokomizo H., Hirata E., Sonoda N., Takayanagi R., GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism 2012 61 10 1422 1434 2-s2.0-84860573353 10.1016/j.metabol.2012.03.002